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Abstract
Background: Dyschromatosis symmetrica hereditaria (DSH) is a rare autosomal dominant cutaneous disorder
caused by the mutations of adenosine deaminase acting on RNA1 (ADAR1) gene. We present a clinical and genetic
study of seven unrelated families and two sporadic cases with DSH for mutations in the full coding sequence of
ADAR1 gene.
Methods: ADAR1 gene was sequenced in seven unrelated families and two sporadic cases with DSH and 120 controls.
Functional significance of the observed ADAR1 mutations was analyzed using PolyPhen 2, SIFT and DDIG-in.
Results: We describe six novel mutations of the ADAR1 gene in Chinese patients with DSH including a nonstop
mutation p.Stop1227R, which was firstly reported in ADAR1 gene. In silico analysis proves that all the mutations
reported here are pathogenic.
Conclusion: This study is useful for functional studies of the protein and to define a diagnostic strategy for mutation
screening of the ADAR1 gene. A three-generation family exhibiting phenotypic variability with a single germline ADAR1
mutation suggests that chilblain might aggravate the clinical phenotypes of DSH.
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Background
Dyschromatosis symmetrica hereditaria (DSH; Mendelian
Inheritance in Man no. 127400) is a rare pigmentary geno-
dermatosis of autosomal dominant inheritance with high
penetrance [1]. Ethnic background appears to be a major
influence on the incidence of this disorder, as it is much
more commonly found in Japanese and Chinese popula-
tions than in others [2]. RNA-specific adenosine deami-
nase 1 (ADAR1) gene, located on chromosome 1q21.3,
was identified to be responsible for DSH [3]. In the
present study, we performed a mutation analysis of the
ADAR1 gene in seven Chinese families and two sporadic




The current study conformed to the tenets of the Helsinki
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study gave their permission for publishing their images.
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Clinical presentations
This study investigated 7 families (Family 1–7) and 2 spor-
adic cases with DSH in the Chinese population. DSH was
diagnosed by experienced dermatologists based on the typ-
ical manifestations and histopathological findings. Seven
multi-generation DSH families exhibited autosomal dom-
inant inheritance. All affected individuals had a typical
mixture of hyperpigmented and hypopigmented macules
on the extremities (Fig. 1a, 1f). These lesions were of
irregular shapes and sizes, which appears during early
childhood, generally ranging from 3 to 15 years. Table 1
summarizes the clinical findings of all the patients analyzed
in this study. Noteworthy is that a variable clinical pheno-
type was observed in family 7. The proband in family 7
was a 23-year-old female. She presented with asymptom-
atic hyperpigmented and hypopigmented macules on her
extremities and had been developing freckle-like macules
on her face since she was 7 years old (Figure 1b, g).
Her mother has only a few small freckle-like pigmented
macules disturbed on the back of her feet (Figure 1h, l).
Whereas her uncle (II:3) had many more asymptomatic hy-
perpigmented and hypopigmented macules on his extrem-
ities than the proband but no freckle-like macules on his
face (Figure 1c, i, m). There is no systematic involvement
was noticed in any of our patients.
Genetic studies
Polymerase chain reactions were performed as described
previously [4]. In addition, samples from 120 unrelated
population-match controls were sequenced for missense
to exclude the possibility that these are polymorphism in
the ADAR1 gene. Mutations were identified by comparing
with the reported cDNA reference sequence (GenBank
accession number: NM_001111).
Results
The entire coding and flanking intronic sequences of
ADAR1 were screened for mutations among 7 families and
Fig. 1 Clinical presentation of dyschromatosis symmetrica hereditaria (DSH) patients. a.. Freckle-like pigmented macules on the face (proband of
family 3, severe phenotype). b. Freckle-like pigmented macules on the face of the proband in family 7. c. No freckle-like macules on the face of
the patient II:3 in family 7. d. Dense freckle-like macules on the neck and face (proband of family 2, severe phenotype). e. Freckle-like pigmented
macules on the face of the sporadic 2. f. Hypopigmented and hyperpigmented macules on the dorsal aspects of the extremities of hands and
feet (proband of family 3, severe phenotype). g. Hypopigmented and hyperpigmented macules on the dorsal aspects of hands of the proband in
family 7 (mild phenotype). h. No any lesion on the dorsal aspect of hand of the patient II:2 in family 7. i, j. Hypopigmented and hyperpigmented
macules on the dorsal aspect of the hand (the patient II:3 in family 7 and the proband in family 2 , severe phenotype). k. Hypopigmented and hy-
perpigmented macules on the dorsal aspect of the hand of the sporadic 2. l. Few small freckle-like pigmented macules disturbed on the back of
the foot (the patient II:2 in family 7). m, n. Hypopigmented and hyperpigmented macules on the back of the foot (the patient II:3 in family 7 and
the proband in family 2, severe phenotype). o. Few small freckle-like pigmented macules disturbed on the back of the foot (the sporadic 2,
mild phenotype)
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2 sporadic patients of Chinese origin with DSH, we de-
tected six novel ADAR1 mutations and two previously
described mutations by direct sequence analysis of the
PCR products (Fig. 2). The spectrum of mutations in-
cluded three nonsense mutations (p.R360X, p.R474X,
p.W768X), one missense mutation p.R1083H, three
frameshift mutations (p.Arg1030ThrfsX1036, p.Gly803
ValfsX807, p.Asp1147ValfsX1184) and one nonstop
mutation p.Stop1227R. We failed to detect any ADAR1
mutation in the sporadic 2.
Three nonsense mutations were identified in the family
4, 6 and the sporadic 1. The mutation c.1078C > T
(p.R360X) was detected in exon 2 in the family 4 (Fig. 2a).
The resulted truncated protein will lack 867 amino acids.
The other nonsense mutation c.1420C > T (p.R474X) was
detected in exon 2 in the family 6 (Fig. 2b). The predicted
protein lacked 753 amino acids. In the sporadic 1, a G >A
mutation was found at nucleotide 2303 that generates a
translational termination codon (Fig. 2c). The predicted
protein lacked 459 amino acid residues.
Table 1 Clinical findings and predicted the effects of the mutations identified in this study





SIFT Polyphen 2.0 DDIG-in
1 Familial 3 7 Back of hands and feet p.R1030DfsX1036 12 Frameshift D - D
2 Familial 7 19 Back of hands and feet, ankles, forearms, neck, face p.Stop1227R 15 Nonstop - - -
3 Familial 6 11 Back of hands and feet, ankles, forearms, face p.G803VfsX807 7 Frameshift D - D
4 Familial 5 18 Back of hands and ankles p.R360X 2 Nonsense - - D
5 Familial 4 8 Back of hands and feet, face p.D1147VfsX1184 14 Frameshift D - D
6 Familial 4 6 Back of hands and feet p.R474X 2 Nonsense - - D
7 Familial 4 4 Back of hands and feet, forearms p.R1083H 13 Missense D D -
1 Sporadic 1 0 Back of hands and feet,face p.W768X 7 Nonsense - - D
2 Sporadic 1 0 Back of hands and feet, face - - - - - -
AI Affected Individuals, UI Unaffected Individuals, D Damaging; −: Not available
Fig. 2 Mutations of the ADAR1 gene found in patients with dyschromatosis symmetrica hereditaria. a. c.1078C>T (p.R360X) mutation in family 4.
b. c.1420C>T (p.R474X) mutation in family 6. c. c.2303G>A (p.W768X) mutation in Sporadic 1. d.c.3248G>A (p.R1083H) mutation in family 7.
e.c.3089_3090delGA (p.R1030DfsX1036) mutation in family 1. f. c.2408delG (p.G803VfsX807) mutation in family 3. g. c.3439ins17 (p.D1147VfsX1184)
mutation in family 5. h. a nonstop mutation TGA(Stop) CGA(Arg)=Stop1227R in family 2
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One missense mutation c.3248G > A was found within
exon 13 and was confirmed in the other patients and
excluded in the remaining unaffected persons (Fig. 2d).
This transition replaced a highly conserved arginine resi-
due with histidine in codon 1083.
Three frameshift mutations were identified in the
family 1, 3 and 5. Nucleotides GA were found to delete
between c.3089 and c.3090 in the family 1 and this 2-
bp small deletion, designated as p.Arg1030ThrfsX1036,
induced a frameshift from codon 1030 and expected to
produce a premature termination codon (PTC) at codon
1036 (Fig. 2e). One single-base deletion c.2408delG was
identified within exon 7 in the family 3 and generated
pre-terminating codon (PTC) at 4 codons downstream
of deletion site (Fig. 2f). The mutation c.3439ins17 was
found within exon 14 in family 5 and this 17-bp insertion
generated a PTC at 37 codons downstream of insertion
site (Fig. 2g). All the above frameshift mutations generated
PTC respectively, and ADAR1 protein synthesis should
end there without translating the full deaminase domain,
which should produce inactive enzymes of ADAR1.
Moreover, a nonstop mutation in the normal stop codon
1227 of ADAR1 gene in exon 15 (TGA(Stop)➙CGA(Arg)
= Stop1227R) (c.3679 T > C) was identified within exon 15
in family 2 (Fig. 2h). Theoretically, the Stop1227R mutation
predictably results in an open reading frame and a mutant-
type (MT) ADAR1 protein containing 1247 amino acid
residues, compared with the 1226 amino acid residues of
wild-type (WT) protein. The additional 21 amino acids
(QYAPVTDGLGCVILGCERGRS) were included into the
ADAR1 protein, with ensuing failure of formation of the
healthy ADAR1 molecule and the development of DSH.
All the mutations except the nonstop mutation
p.Stop1227R were predicted to be damaging. This pre-
diction is based on the information from SIFT (http://
sift.jcvi.org) [5], PolyPhen 2 (http://genetics.bwh.harvar-
d.edu/pph2/) [6] and DDIG-in (http://sparks-lab.org/
yueyang/server/ddig/) [7]. All the changes affect highly
evolutionally conserved amino acids (Fig. 3).
Discussion
ADAR1, also called DSRAD (double-stranded RNA-
specific adenosine deaminase), belongs to a family of RNA-
specific adenosine deaminase that represents one type of
RNA editing enzyme. It contains at least six functional do-
mains: two Zalpha (Z-DNA-binding domain in adenosine
deaminases), three DSRM (double-stranded RNA binding
motif) and a tRNA-specific and double-stranded RNA ad-
enosine deaminase (ADEAMc) domains. They are located
in exon 2, exons 2–7 and exons 9–15, respectively [8].
In this study, we detected six novel ADAR1 mutations
and two previously described mutations among 7 families
and 2 sporadic patients of Chinese origin with DSH. The
nonsense mutations (p.R360X, p.R474X and p.W768X)
and single-base deletion c.2408delG (p.G803VfsX807) are
expected to cause ADAR1 truncations lacking the entire
ADEAMc domain while the other two frameshift muta-
tions p.R1030TfsX1036 and p.D1147VfsX1184 in our
study supposed to cause ADAR1 truncations lacking the
partial ADEAMc domain, which should produce inactive
enzymes of ADAR1 and ensue the development of this
disease. All the frameshift indels were predicted to be
deleterious by both SIFT and DDIG-in, all the nonsense
mutations were predicted to be deleterious by DDIG-in
and missense mutation c.3248G >A was predicted to be
potentially damaging by both SIFT and Polyphen2.0
(Table 1). It is also possible that the mutant ADAR1 pro-
tein may not exist at all in these affected patients based on
nonsense-mediated mRNA decay (NMD). NMD is a sur-
veillance mechanism by which cells recognize and degrade
mRNAs containing premature translation termination co-
dons [9]. In family 5, we detected a nonsense mutation
p.R474X, this mutation has been detected most frequently
so far, and has been reported five times [3, 4, 10]. The hot-
spot mutation p.R474X has previously been reported in
Chinese [4, 10] and also in Japanese [3] in many studies,
indicating a possible founder effect of this mutation. No
mutation was found in one sporadic 2 although he pre-
sents typical lesions of DSH (Fig. 1e, k, o). It is possible
that the pathogenic mutation is regulatory ones within the
promoter region or non coding regions. Such mutations
will be missed in the current study where only the coding
sequences and the exon-intron boundary sequences were
targeted [4].
Of interest, we identified a nonstop mutation, c.3679 T >
C (p.Stop1227R), in family 2. To our knowledge, this is a
novel mutation and firstly reported in ADAR1 gene.
Previous reports found that nonstop mRNA mutations
associated with Diamond-Blackfan anemia [11], mucopoly-
saccharidosis II [12] and FX-coagulation deficiency [13]
always result in pronounced reduction of steady-state levels
of mutant mRNA. In contrast, quantitative real-time PCR
and 3’-RACE-RFLP analysis revealed unreduced non-
stop mRNA levels in the patient with mitochondrial
neurogastrointestinal encephalomyopathy harboring a
nonstop mRNA mutation (c.1416delC) in the TYMP
gene [14]. However, we could not obtain experimental
evidence because we lost contact with the patients in
the family and could not get an additional blood sample
for the quantitative real-time PCR and 3’-RACE-RFLP
analysis. The proband in this family presented with se-
vere phenotype including dense freckle-like macules on
his neck and face, and multiple dense hyper- and hypo-
pigmented lesions on the back of his hands and feet
(Fig. 1d, j, n). Further functional studies are required to
elucidate the pathomechanisms of the severe DSH
underlying this nonstop mutation. Although still very
much speculative, the following pathomechanisms of the
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severe DSH underlying this mutation may be considered:
i) The p.Stop1227R mutation predictably results in an
open reading frame and a mutant-type (MT) ADAR1 pro-
tein containing 1247 amino acid residues, compared with
the 1226 amino acid residues of wild-type (WT) protein.
The additional 21 amino acids (QYAPVTDGLGCVILG-
CERGRS) were included into the ADAR1 protein, with
ensuing failure of formation of the healthy ADAR1 mol-
ecule. ii) It is likely that the mutant mRNA of ADAR1
gene in family 2 were reduced duing to nonstop mRNA
decay, which was recently identified and showed to reduce
the accumulation of abnormal transcripts lacking in-frame
termination codons [11–13]. iii) The c.3679 T > C nonstop
mRNA molecules are as stable as those transcribed from
the wild-type alleles in this family but the translation of
mutant transcript is repressed and/or its protein product
is not stable [14].
Moreover, family 7 exhibits a phenotypic variability with
a single germline mutation in ADAR1. The proband’s
mother only has few small freckle-like pigmented macules
disturbed on the back of her feet (Fig. 1l) whereas her
uncle had much more asymptomatic hyperpigmented and
Fig. 3 All the mutations except the nonstop mutation p.Stop1227R were predicted to be damaging. a. Heatmap of PSSM for single mutations
(p.R360X, p.R474X, p.W768X and p.R1083H). The red color indicates more conservation while blue indicates less conservation. b. Heatmap of PSSM for
Indels (p.G803VfsX807, p.R1030DfsX1036 and p.D1147VfsX1184). The red color indicates more conservation while blue indicates less conservation.
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hypopigmented macules on his extremities (Fig. 1i, m).
According to his medical history, he used to have chilblain
on his hands and feet during winter. Meanwhile, he had
severe chilblain manifestated as blisters and erosions,
which might have caused hypopigmented and hyperpig-
mented macules on his skin, which then aggravate the
clinical presentation of DSH. In this family, we detected a
missense mutation p.R1083H in ADAR1 gene, this muta-
tion has been reported in the Japanese family and its pa-
tients are early-onset (under one year old) [15], while the
proband in our family had her lesions since the age of 7.
To sum up, we found that the same mutation could lead
to different phenotypes even in the same family and did
not establish a clear correlation between genotypes and
phenotypes, thereby suggesting that phenotype is not ex-
plained by genotype alone and some factors, such as viral
infection in utero and/or in infancy and exposure to ultra-
violet light as well as chilblain in our patient, may affect
the phenotype expression [1]. Li et al. compared the clin-
ical features with the mutation identified in all families,
but they also did not find a clear correlation between
genotypes and phenotypes [4].
Conclusion
We have reported six novel mutations including a non-
stop mutation p.Stop1227R, which was firstly reported
in ADAR1 gene. Furthermore, we reported a three-
generation family exhibiting phenotypic variability with
a single germline ADAR1 mutation and chilblain might
aggravate the clinical phenotypes of DSH. The ongoing
recognition of different mutations may give insight into
the still unknown mechanisms involved in the develop-
ment of DSH.
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